Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiniferatoxin - Sorrento Therapeutics

Drug Profile

Resiniferatoxin - Sorrento Therapeutics

Alternative Names: MCP 101; RTX

Latest Information Update: 29 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer pain; Pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 22 Aug 2022 Phase-II clinical trials in Cancer pain (Late-stage disease) in USA (Epidural) (NCT05067257) (Sorrento Therapeutics pipeline; August 2022)
  • 07 Dec 2021 Phase-II clinical trials in Pain in USA (Intra-articular)
  • 09 Nov 2021 Sorrento Therapeutics withdraws a phase III trial for Pain (associated with knee osteoarthritis) prior to enrolment (Intra-articular, Injection) (NCT04044742)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top